Secura Bio Patent-Cliff Exposure & CMS Drug Spending Portfolio

Secura Bio (US): 1 reconciled FDA prescription therapies, $36.9M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$36.9M
2024 Medicare Part D Spend$31.4M
2024 Medicaid Spend$5.5M
California HCAI SB 17 Filings4 WAC filings (max 94.0% 2-yr change)